Coagulation factor IXa as a target for treatment and prophylaxis of venous thromboembolism.
Venous thromboembolism remains a frequent cause of vascular death. Despite advances in anticoagulant drug development, unmet needs remain, including limited treatment options for patients with severe renal impairment and the inability to fully reverse the effects of anticoagulants approved or in late-stage development. Because coagulation factor IXa plays a pivotal role in tissue factor-mediated thrombin generation, it represents an attractive target for anticoagulant development. This article discusses the rationale for factor IXa as an anticoagulant target and the potential role in venous thromboembolism prevention or management of the 2 factor IXa inhibitors that have undergone testing in phase 1 or 2 trials: TTP889, an oral, small-molecule compound, and RB006, an aptamer-based compound, the intravenous and subcutaneous formulations of which are the anticoagulant components of the REG1 and REG2 anticoagulation systems, respectively.
Regado Biosciences, Inc., 318 Blackwell St, STE 130, Durham, NC 27701, USA.
John W
JW
Eikelboom
Steven L
SL
Zelenkofske
Christopher P
CP
Rusconi
D000925:Anticoagulants / Q000008:administration & dosage / Q000627:therapeutic use; D052157:Aptamers, Nucleotide / Q000008:administration & dosage / Q000627:therapeutic use; D015949:Factor IXa / Q000037:antagonists & inhibitors*; D006801:Humans; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D020246:Venous Thrombosis / Q000517:prevention & control* / Q000628:therapy*
D000925:Anticoagulants; D052157:Aptamers, Nucleotide; C515724:RB 006; D015949:Factor IXa